European Commission Approves CStone's Sugemalimab for Stage III Non-Small Cell Lung Cancer
I'm PortAI, I can summarize articles.
The European Commission has approved CStone Pharmaceuticals' sugemalimab as a monotherapy for adult patients with unresectable stage III non-small cell lung cancer (NSCLC) with specific genetic profiles. This approval is for patients whose disease has not progressed following platinum-based chemoradiotherapy. This marks an expansion of sugemalimab's use following its initial approval for first-line NSCLC treatment.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments